Vitaeris
Vancouver
About Vitaeris
Vitaeris has licensed global exclusive rights to the best-in-class anti-interleukin-6 monoclonal antibody Clazakizumab from Alder Biopharmaceuticals, and is actively pursuing innovative applications in chronic inflammatory diseases.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $7.0M
- Funding stage: M&A
- Last round: Seed (Jun 2016)
- Website: vitaerisbio.com
- Phone: +1 (800)518-5253
Industries & Categories
Biotechnology, Health Care, Medical, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/vitaeris-189342 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.